98%
921
2 minutes
20
Introduction: Appalachian communities experience elevated rates of cancer incidence and mortality relative to other regions in the U.S. Specifically, melanoma mortality rates are higher in Appalachia compared to the national average, despite comparable incidence rates.
Purpose: To examine differences in self-reported history of skin cancer and prevalence of two UV exposure behaviors between Appalachian and non-Appalachian adults in a nationally representative sample.
Methods: Data are from four cross-sectional cycles of the Health Information National Trends Survey (2011-2014) (N=14,451). We examined sunscreen use and tanning bed use, and self-reported history of melanoma and non-melanoma skin cancer. Descriptive and weighted multivariable analyses were conducted to examine sunscreen and tanning bed use, controlling for sociodemographic characteristics.
Results: Approximately 8% of the study sample resided in Appalachia (n=1,015). Self-reported melanoma (0.6%) and non-melanoma (3.2%) skin cancer histories were low among Appalachians and did not differ statistically from non-Appalachians (>0.05). Only 21.2% of Appalachians reported using sunscreen often or always when going outside for more than one hour on a warm, sunny day compared to 27.4% of non-Appalachians (p=0.04), but there were no regional differences in tanning bed use (OR=1.48, p=0.23) when controlling for sociodemographics and general health status.
Implications: Appalachians had comparable histories of self-reported melanoma and non-melanoma skin cancer but were less likely to report sunscreen use than non-Appalachians. Enhanced communication efforts to promote sunscreen use and other UV protection behaviors in Appalachia may be valuable.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138723 | PMC |
http://dx.doi.org/10.13023/jah.0202.06 | DOI Listing |
Radiol Med
September 2025
Breast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.
Metastatic involvement (MB) of the breast from extramammary malignancies is rare, with an incidence of 0.09-1.3% of all breast malignancies.
View Article and Find Full Text PDFPediatr Blood Cancer
September 2025
Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Background: The suppressor of tumorigenesis 2 (ST2) has emerged as one of the most promising biomarkers for predicting mortality of acute graft-versus-host disease (aGvHD) when measured at the onset of symptoms, but detailed time course studies are needed to understand the potential of ST2 as a risk marker of both aGvHD and chronic graft-versus-host disease (cGvHD), potentially allowing pre-emptive adjustment of immunosuppressive treatment.
Procedure: We measured ST2 levels in 117 children undergoing standard hematopoietic stem cell transplantation (HSCT) before conditioning and at regular intervals post-HSCT.
Results: ST2 levels were significantly increased from Day +7 in patients developing aGvHD of any grade (no GvHD: 23.
Ophthalmic Plast Reconstr Surg
September 2025
Division of Surgery, Department of Ophthalmology.
An 84-year-old Caucasian male was referred for evaluation of a worsening left medial canthal lesion for consideration of excision. The patient reported a 4-year history of the painless canthal lesion gradually increasing in size with progressively obstructed peripheral vision. On examination, the cream-colored cyst measured 10 × 8 mm.
View Article and Find Full Text PDFJ Biomed Opt
December 2025
University of Toronto, Department of Medical Biophysics, Temerty Faculty of Medicine, Toronto, Ontario, Canada.
Significance: Tumor tissues exhibit contrast with healthy tissue in circular degree of polarization (DOP) images via higher magnitude circular DOP values and increased helicity-flipping. This phenomenon may enable polarimetric tumor detection and surgical/procedural guidance applications.
Aim: Depolarization metrics have been shown to exhibit differential responses to healthy and cancer tissue, whereby tumor tissues tend to induce less depolarization; however, the understanding of this depolarization-based contrast remains limited.
Cureus
August 2025
Dermatology, Hôpital Privé Francheville, Perigueux, FRA.
Risankizumab (RZB) is a humanized monoclonal antibody that selectively targets interleukin-23 (IL-23). It has proven particularly effective in treating psoriasis, a common chronic inflammatory skin disease. However, its use remains poorly documented in certain populations, including patients with a history of solid organ transplantation or recent/active malignancy.
View Article and Find Full Text PDF